Cadigan RJ, Edwards TP, Lassiter D, Davis AM, Henderson GE. "Forward-Thinking" in U.S. biobanking. Genet Test Mol Biomark. 2017 Mar;21(3):148-54. doi: 10.1089/gtmb.2016.0393
Vass C, Gray E, Payne K. Discrete choice experiments of pharmacy services: a systematic review. Int J Clin Phar. 2016 Jun;38(3):620-30. doi: 10.1007/s11096-015-0221-1
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Price MA, Hill CD, Williams VSL, Morlock RJ, Leeuwenkamp O, Patterson TL. Measures of functional status and quality-of-life in schizophrenia. Curr Psychiatry Rev. 2008 Feb 1;4(1):28-38.
Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, Levine KB, Jordan J, Clark RV. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008 Jan 1;11(1):32-43.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.